| Filed On | Filing |
|---|---|
| 23 Oct 2026 |
8-K/A: Financial Statements and Exhibits
On August 10, 2026, Amneal Pharmaceuticals, Inc., a Delaware corporation (“Amneal” or the “Company”), completed the acquisition (the “Transaction”) of Kashiv BioSciences, LLC, a Delaware limited liability company (“Kashiv”). The followin... |
| 05 Aug 2025 |
8-K/A: Submission of Matters to a Vote of Security Holders
As previously reported in the Original Form 8-K, in an advisory vote held at the Annual Meeting on the Say-on-Frequency Proposal, our stockholders expressed their preference for a Say-on-Pay Vote to be conducted every year. Consistent wi... |
| 12 Nov 2024 |
8-K/A: Results of Operations and Financial Condition; Regulation FD Disclosure
‒ Q3 2024 Net Revenue of $702 million; GAAP Net Loss of $0.2 million; Diluted Loss per Share of $0.00 ‒ |
| 15 Dec 2023 |
8-K/A: Financial Statements and Exhibits
SECTION 1. OFFICES. Amneal NewCo Inc. (the “Corporation”) shall maintain its registered office in the State of Delaware at 1209 Orange Street, City of Wilmington, County of New Castle, 19801, and its resident agent at such address is the... |
| 17 Apr 2020 |
8-K/A: Financial Statements and Exhibits
The following unaudited pro forma condensed combined financial information of Amneal Pharmaceuticals, Inc. (“Amneal”) is presented to illustrate the estimated effects of: |
| 20 Feb 2020 |
8-K/A: Departure/Election of Directors or Officers; Compensation
On February 18, 2020, the Board of Directors of the Company (“the Board”) appointed, effective immediately, Jeffrey P. George to the Board’s Audit Committee, Compensation Committee and Conflicts Committee and the Board’s newly formed Tec... |
| 20 Feb 2020 |
8-K/A: Departure/Election of Directors or Officers; Compensation
On February 18, 2020, the Board of Directors of the Company (“the Board”) appointed, effective immediately, Paul M. Meister to the Board’s Compensation Committee and Nominating and Corporate Governance Committee and the Board’s newly for... |
| 01 Mar 2019 |
8-K/A: Financial Statements and Exhibits
We have audited the accompanying consolidated balance sheets of Impax Laboratories, Inc. and subsidiaries (the Company) as of December 31, 2017 and 2016, and the related consolidated statements of operations, comprehensive (loss) income,... |
| 12 Jul 2018 |
8-K/A: Financial Statements and Exhibits
This unaudited pro forma condensed combined financial information and explanatory notes of Amneal Pharmaceuticals, Inc. (“New Amneal” or the “Company”) present how the consolidated financial statements of New Amneal may have appeared had... |
| 10 May 2018 |
8-K/A: Financial Statements and Exhibits
The audited consolidated balance sheets of Impax as of December 31, 2017 and December 31, 2016, the related audited consolidated statements of operations, comprehensive (loss) income, changes in stockholders’ equity and cash flows for Im... |
Loading...